- Alemtuzumab and autoimmune haemolytic anaemia: Coincidence or causation? [Journal Article]Vox Sang. 2023 Jan 22 [Online ahead of print]VS
- Publisher Full Text (DOI)
- Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study. [Journal Article]Clin Exp Med. 2023 Jan 15 [Online ahead of print]CE
- Autoimmune thyroid disease (AITD) is the most common adverse effect in alemtuzumab (ALZ) treated relapsing-remitting (RR) multiple sclerosis (MS) patients. The objective of this prospective study was to analyze the occurrence, timing of onset, clinical course, and laboratory characteristics of AITD post-ALZ. We evaluated 35 RRMS patients treated with ALZ at a single academic MS center; clinical a…
- Publisher Full Text (DOI)
- Disseminated Mycobacterium haemophilum infection during alemtuzumab treatment of T-cell prolymphocytic leukemia. [Letter]Ann Hematol. 2023 Jan 13 [Online ahead of print]AH
- Publisher Full Text (DOI)
- Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. [Journal Article]J Clin Oncol. 2023 Jan 09 [Online ahead of print]JC
- CONCLUSIONS: Low-intensity regimens rely on tolerance induction and establishment of mixed-donor chimerism. Persistence of host cells exposed to low-dose radiation triggering myeloid malignancy is one plausible etiology. Pre-existing myeloid mutations and prior inflammation may also contribute but could not be studied using our data source. Choosing conditioning regimens likely to result in full-donor chimerism may in part mitigate the higher risk for leukemia/MDS.
- Publisher Full Text (DOI)
- Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. [Journal Article]
- CONCLUSIONS: Adjudicated thyroid events occurring over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients were primarily autoimmune. Thyroid events were considered manageable and did not affect disease course. Thyroid autoimmunity is a common but manageable adverse event in alemtuzumab-treated relapsing multiple sclerosis patients.ClinicalTrials.gov Registration Numbers: CARE-MS I (NCT00530348); CARE-MS II (NCT00548405); CARE-MS Extension (NCT00930553).
- PMC Free PDF
- Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion. [Journal Article]Transplant Cell Ther. 2022 Dec 30 [Online ahead of print]TC
- After allogeneic stem cell transplantation (alloSCT), patient-derived stem cells that survived the pretransplantation conditioning compete with engrafting donor stem cells for bone marrow (BM) repopulation. In addition, donor-derived alloreactive T cells present in the stem cell product may favor establishment of complete donor-derived hematopoiesis by eliminating patient-derived lymphohematopoie…
- Publisher Full Text (DOI)
- Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience. [Journal Article]Transpl Immunol. 2022 Dec 28; 77:101778.TI
- CONCLUSIONS: Induction immunosuppression utilizing Basiliximab is associated with significant reduction in development of de novo DSA within the first 12-months post kidney transplant but had lower creatinine clearance with long-term follow up.
- Publisher Full Text (DOI)
- Circulating CCR6+ILC proportions are lower in multiple sclerosis patients. [Journal Article]
- CONCLUSIONS: CD56bright NK cells during relapse indicate an immediate response to disease reactivation, while CCR6-related shifts among helper ILC suggest altered ILC migration to the CNS during MS.
- PMC Free PDF
- Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. [Journal Article]Neurology. 2022 Dec 21 [Online ahead of print]Neur
- CONCLUSIONS: The use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared to standard immunotherapy.
- Publisher Full Text (DOI)
- [Follow up examination of multiple sclerosis patients treated with alemtuzumab in Multiple Sclerosis Centre, Szeged]. [Journal Article]Ideggyogy Sz. 2022 Nov 30; 75(11-12):377-384.IS
- CONCLUSIONS: The tight follow-up of the treated patients and the precise documentation of the register enable the comparison of results yielded by placebo controlled clinical studies with daily practice, as well as to gain information on the benefits of induction therapy as a paradigm shift in treating MS patients.
- Publisher Full Text (DOI)
- Neurological complications following pediatric allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. [Journal Article]
- CONCLUSIONS: Infectious and noninfectious NCs are a significant cause of morbidity and mortality following allogeneic HSCT in children. Further research is required to better understand the risk factors for different NCs and their outcomes regarding sequelae and survival.
- PMC Free PDF
- Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA. [Journal Article]J Comp Eff Res. 2023 Jan; 12(1):e220127.JC
- Aim: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). Patients & methods: Retrospective, observational study of IBM®MarketScan® claims database. PwMS previously treated with DMTs and initiating alemtuzumab (1 January 2013 to 31 December …
- Publisher Full Text (DOI)
- The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study. [Journal Article]Mult Scler Relat Disord. 2022 Nov 21; 69:104423.MS
- CONCLUSIONS: Our results show that spinal cord and Gd MRI acquisitions can provide relevant information to influence subsequent treatment decisions, especially in early treatment phases, compared with stand-alone brain MRI.
- Publisher Full Text (DOI)
- Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis. [Meta-Analysis]Neurol Neurochir Pol. 2022; 56(6):480-489.NN
- CONCLUSIONS: Of all considered therapies, treatment with cladribine tablets was associated with a higher probability of sustained disability improvement in RRMS patients. As this conclusion is based on available clinical data of limited quality, future studies, as well as real-world data, would be valuable to provide further evidence regarding the comparative effectiveness of RRMS therapies.
- Publisher Full Text (DOI)
- Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation. [Journal Article]Br J Clin Pharmacol. 2022 Nov 21 [Online ahead of print]BJ
- CONCLUSIONS: Alemtuzumab displays substantial pharmacokinetic variability in kidney transplant recipients, which may warrant a personalised treatment strategy. Lean bodyweight-adjusted dosing poses an option for individualised dosing, but further evaluation of its potential clinical benefit is warranted.
- Publisher Full Text (DOI)
- Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study. [Journal Article]
- CONCLUSIONS: The primary endpoint was met; the safety of alemtuzumab was consistent with pivotal studies.
- PMC Free PDF
- Outcomes of Primary Simultaneous Pancreas-kidney Transplants by Induction Agent in the United States. [Journal Article]
- CONCLUSIONS: r-ATG use was associated with the lowest SPK rejection rates. Compared with r-ATG, alemtuzumab but not IL-2RA was associated with worse long-term death-censored SPK graft outcome. Our analysis supports the common use of r-ATG for induction in US primary SPK recipients.
- PMC Free PDF
- Severe Autoimmune intravascular hemolytic anemia in patients receiving Alemtuzumab for Multiple sclerosis. [Journal Article]Blood Adv. 2022 Nov 14 [Online ahead of print]BA
- Publisher Full Text (DOI)
- Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature. [Review]
- Cutaneo us vasculitis (CV) has a broad spectrum of etiologies, and drugs are one of the main culprits. With the increasing use of targeted therapies in medicine, especially in rheumatology and oncology, the number of CV cases reported due to these drugs has increased. Therefore, the recognition and treatment of CV associated with targeted agents have become more and more important. In the literat…
- Publisher Full Text (DOI)
- Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database. [Journal Article]Haemophilia. 2023 Jan; 29(1):186-192.H
- CONCLUSIONS: This worldwide pharmaco-epidemiologic study updates the list of the drugs associated with AHA. The clinician should be aware of these possible severe ADR, which might require larger epidemiological and pathophysiologic studies.
- Publisher Full Text (DOI)
- Trans-Endothelial Migration of Memory T Cells Is Impaired in Alemtuzumab-Treated Multiple Sclerosis Patients. [Journal Article]
- The breakdown of the blood-brain barrier (BBB) and the trans-endothelial migration of lymphocytes are central events in the development of multiple sclerosis (MS). Autoreactive T cells are major players in MS pathogenesis, which are rapidly depleted following alemtuzumab treatment. This modulation, in turn, inhibits CNS inflammation, but alemtuzumab's effect on T cell migration into the CNS has b…
- PMC Free PDF
- High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. [Review]
- There are > 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS). Given the multitude of available treatment options, and recent international consensus guidelines offering differing recommendations, there is broad heterogeneity in how the DM…
- PMC Free PDF
- A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis. [Review]Ann Pharmacother. 2022 Nov 09 [Online ahead of print]AP
- CONCLUSIONS: Improvements in diagnostic methods and novel immunosuppressive treatment strategies, including noncytotoxic immunochemotherapy, have transformed the therapeutic landscape. Unfortunately, many unanswered questions remain. Additional studies are required to optimize dosing, schedules, treatment sequences, and indications for novel treatment options.
- Publisher Full Text (DOI)
- Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients. [Journal Article]Transplant Cell Ther. 2022 Nov 09 [Online ahead of print]TC
- Epstein-Barr virus (EBV) reactivation and EBV-related post-transplantation lymphoproliferative disorder (PTLD) are often fatal complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The risk of EBV reactivation may be mitigated by depletion of B cells with rituximab. Starting in January 2020, allo-HSCT recipients undergoing T-cell depletion with alemtuzumab received 1…
- Publisher Full Text (DOI)
- Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients. [Journal Article]
- The measurement of serum neurofilament light chain (sNfL) is of growing importance in the field of neurology. In the management of multiple sclerosis, it can serve as a useful marker to assess disease activity and treatment response. This paper compares two available methods, namely the Single Molecule Array (Simoa) and the Ella microfluid platform, to measure longitudinal sNfL levels of 42 highl…
- PMC Free PDF
- Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. [Clinical Trial, Phase I]
- Genome editing of allogeneic T cells can provide "off-the-shelf" alternatives to autologous chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain (TRAC) to prevent graft-versus-host disease (GVHD) and removal of CD52 (cluster of differentiation 52) for a survival advantage in the presence of alemtuzumab have previously been investigated using transcription activa…
- Publisher Full Text (DOI)
- UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. [Clinical Trial, Phase I]
- CONCLUSIONS: UCART19 had a manageable safety profile, and showed evidence of antileukaemic activity in heavily pretreated adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. This study shows that allogeneic off-the-shelf CAR T cells can be used safely to treat patients with relapsed B-cell acute lymphoblastic leukaemia.
- Publisher Full Text (DOI)